CatalYm
CatalYm is a biotechnology company committed to developing innovative immunotherapies for cancer patients. CatalYm has identified GDF-15 as a central regulator of the immune system in the tumor microenvironment and translates the therapeutic potential of neutralizing GDF-15 into meaningful clinical responses for patients with solid tumors. CatalYm’s CTL-002 program is poised to demonstrate clinical proof-of-concept in multiple solid tumor indications and has the potential to expand the treatment horizon for current and future immunotherapies.
Tech Stack (20 technologies)
Frequently Asked Questions
What technologies does CatalYm use?+
CatalYm uses 20 technologies including AOS, Contact Form 7, Modernizr.
What industry is CatalYm in?+
CatalYm operates in the Biotechnology industry.
Where is CatalYm based?+
CatalYm is headquartered in Germany.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026